SCHEMBL5033537

SCHEMBL5033537

O=C(Nc1nc2cc(OS(=O)(=O)c3ccc(N4CCCN(CCCN5CCCC5)CC4)cc3)ccc2[nH]1)C1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTR1A P08908 2/20 0.39
KCNH2 Q12809 1/20 0.39
ABL1 P00519 2/20 0.38
MEN1 O00255 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
GFER P55789 1/20 0.37
ENPP3 O14638 5/20 0.36
ENPP1 P22413 4/20 0.36
ENPP2 Q13822 3/20 0.36
PARP1 P09874 1/20 0.36
TUBB4A P04350 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5037858 0.91 SMN1; SMN2 (0.42) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL5033793 0.91 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL5033727 0.90 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL5040873 0.90 ABL1 (0.44) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL5037985 0.89 SMN1; SMN2 (0.39) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL5040951 0.89 MMP2 (0.43) SMN1; SMN2NPC1RAB9AHTR1AMEN1
SCHEMBL5033454 0.88 ABL1 (0.46) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL5036504 0.87 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL5036013 0.86 SMN1; SMN2 (0.44) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL5037583 0.86 ENPP3 (0.43) SMN1; SMN2NPC1RAB9APOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432417-B1 SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER AVENTIS PHARMA SA (FR) 2008-02-20 EP disclosed
US-7041668-B2 Substituted benzimidazole compounds and their use for the treatment of cancer AVENTIS PHARMA S.A. (FR) 2006-05-09 US disclosed
US-20050014811-A1 Substituted benzimidazole compounds and their use for the treatment of cancer AVENTIS PHARMA S.A. (FR) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014811-A1 Substituted benzimidazole compounds and their use for the treatment of cancer CDKL3, CCNL2, CDKL1 SMN1; SMN2 2426/4885NPC1 3782/4885RAB9A 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.